Plixorafenib (FORE8394)
Advanced, unresectable solid tumors harboring BRAF alterations (V600, non-V600, fusions, amplifications)
Phase 2Active
Key Facts
Indication
Advanced, unresectable solid tumors harboring BRAF alterations (V600, non-V600, fusions, amplifications)
Phase
Phase 2
Status
Active
Company
About Fore Biotherapeutics
Fore Biotherapeutics is a private, pre-revenue biotech advancing a targeted oncology pipeline, anchored by its lead asset plixorafenib. The company is currently conducting a Phase 2 basket trial (FORTE) to evaluate plixorafenib's efficacy and safety in advanced solid tumors with various BRAF alterations, having recently reported positive interim data. Operating with a virtual model, Fore is backed by top-tier investors and focuses on in-licensing clinic-ready compounds to rapidly deliver therapies to patients with limited treatment options.
View full company profile